Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Antisense oligonucleotide targeted to the SMN2 gene

EU orphan designation number: EU/3/12/976   
Active ingredient: Antisense oligonucleotide targeted to the SMN2 gene
Indication: Treatment of 5q spinal muscular atrophy
Sponsor: Isis USA Ltd
c/o Arnold & Porter (UK) LLP Tower 42, 25 Old Broad Street, London, EC2N 1HQ, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
04/04/2012 Centralised Orphan - Designation EMA/OD/141/11 (2012)2346 of 02/04/2012